Case studies

Client situation

A biotechnology company developing a peptide-based asset intended to preserve or increase muscle mass during GLP-1-associated weight loss needed early commercial clarity before heavier investment in clinical and partnering plans.

Commercial question

Is muscle preservation a meaningful unmet need, which patient groups matter most, how should the product be positioned, and what evidence would drive physician and payer adoption?

Research approach

• Specialist physician interviews across priority markets
• Payer and market-access interviews
• Competitive landscape review
• Patient-segment prioritisation
• Treatment-pathway analysis
• Early target product profile recommendations
• Preliminary market sizing and executive workshops

Participants & markets

Approximately 34 specialist physician interviews and 9 payer / market-access interviews

United States and major European markets

Deliverables

• Indication and segment prioritisation
• Positioning options (preventative vs restorative; adjunct to GLP-1)
• Endpoint guidance for adoption
• Payer evidence implications
• Preliminary commercial framing

Commercial impact

Gives leadership a commercially usable view of where to play, what to prove next, and how to frame partnering discussions, explicitly labelled as an illustrative methodology, not a claimed completed client win.

Client situation

A client evaluating a rare-disease asset needed a clearer picture of diagnosis delay, specialist referral and treatment initiation in concentrated centres.

Commercial question

Where do patients drop out of the pathway, which centres drive decisions, and what evidence would change prescribing?

Research approach

• Specialist centre interviews
• Patient and caregiver interviews where appropriate
• Pathway mapping workshops
• Competitive and standard-of-care review

Participants & markets

Specialist clinicians and selected patient / caregiver respondents

Selected EU5 and US specialist centres

Deliverables

• Pathway maps
• Barrier analysis
• Centre-of-excellence implications
• Evidence and messaging priorities

Commercial impact

Representative methodology for concentrated pathways where desk research alone cannot explain real-world access and initiation.

Client situation

An oncology development team needed to compare profile options before locking endpoints and positioning language.

Commercial question

Which efficacy, safety, dosing and monitoring attributes drive specialist adoption, and which are deal-breakers?

Research approach

• Structured qualitative trade-off interviews
• Profile card testing
• Line-of-therapy scenario discussion
• Synthesis into profile recommendations

Participants & markets

Specialist oncologists across relevant tumour settings

Multi-market specialist sample

Deliverables

• Attribute importance
• Adoption drivers and barriers
• Recommended profile narrative
• Implications for evidence generation

Commercial impact

Illustrates how Sentio turns specialist response into a clear product-profile recommendation for development and commercial teams.

Client situation

A specialty therapy required a realistic view of how dermatology consultants would place a new option in routine practice.

Commercial question

What drives switching, persistence and patient selection among practising dermatologists?

Research approach

• Consultants practising in routine clinical settings
• Treatment-decision interviews
• Message and concept response
• Competitive context review

Participants & markets

Dermatology specialists with relevant prescribing experience

Priority European and US markets as scoped

Deliverables

• Adoption barriers and levers
• Patient-selection criteria
• Message priorities
• Implications for commercial planning

Commercial impact

Shows the value of proximity to clinicians who prescribe every day, not only key-opinion-leader commentary.